Structural genomics and drug discovery.
Structure determination has already proven useful for lead optimization and direct drug design. The number of high-resolution structures available in public databases today exceeds 30,000 and will definitely aid in structure-based drug design. Structural genomics approaches covering whole genomes, topologically similar proteins or gene families are great assets for further progress in the development of new drugs. However, membrane proteins representing 70% of current drug targets are poorly characterized structurally. The problems have been related to difficulties in obtaining large amount of recombinant membrane proteins as well as their purification and structure determination. Structural genomics has proven successful in developing new methods in areas from expression to structure determination by studying a large number of target proteins in parallel.
Lundstrom
K
K
Flamel Technologies, 33 Avenue du Dr. Georges Lévy, 69693 Vénissieux, France. lundstrom@flamel.com
D000818:Animals; D018360:Crystallography, X-Ray; D015195:Drug Design; D005544:Forecasting; D023281:Genomics; D006801:Humans; D008854:Microscopy, Electron; D019906:Nuclear Magnetic Resonance, Biomolecular; D011506:Proteins / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D013329:Structure-Activity Relationship
D011506:Proteins; D011994:Recombinant Proteins